Navigation Links
Is Nexium? beneficial for patients with Zollinger-Ellison syndrome?

Los Angeles-A novel study has revealed that the proton pump inhibitor (PPI) NEXIUM? (esomeprazole magnesium) is capable of maintaining normal gastric acid levels// in those patients suffering Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion (IGH).

Zollinger-Ellison syndrome (ZES), a rare but serious chronic condition, is characterized by the development of a tumor or tumors that secrete excessive levels of gastrin, a hormone that stimulates acid production by the stomach. ZES is rare, affecting fewer than three out of every million Americans (less than 1,000 people)1, but it is chronic, difficult to treat, and may be life-threatening. Most people with ZES are prone to recurrent gastric and duodenal ulcers; other symptoms include abdominal pain, diarrhea and increased fat in the stools.

Twenty-one patients received one of several doses of NEXIUM, depending on the degree of their acid output and symptoms at various times throughout the trial. The results showed that at 12 months, NEXIUM 40 mg twice daily controlled basal acid output (AO) in 14 study participant (67 percent), NEXIUM 80 mg twice daily was required to control AO in 4 study participants (19 percent), and NEXIUM 80 mg given three times daily maintained AO in 1 study participant. (Adequate acid output control was defined as <5 mmol/h for patients who had prior gastric-acid-reducing surgery, and as <10 mmol/h for patients who hadn't had the surgery.) Further, 18 of 20 patients whose acid was controlled by day 10 maintained control for the duration of the study. No patients showed evidence of erosive esophagitis or gastric or duodenal (located in the upper region of the small intestine) ulcers at 12 months.

"Zollinger-Ellison syndrome places individuals under constant attack from higher than normal amounts of acid that their stomachs produce. Therefore, people with the condition require treatment that can continuously interfere with this faulty mechanism ," said lead investigator David Metz, MD, Professor of Medicine, and the Director of the Acid-Peptic Program, Division of Gastroenterology, University of Pennsylvania Health System. "The study shows that NEXIUM provided early and sustained acid suppression to help control symptoms of the disease. These results corroborate previous research on the effectiveness of PPIs in treating gastric acid hypersecretion."

Study Details

The 12-month, open-label trial evaluated the effects of NEXIUM on basal acid output (AO) control in patients with ZES or idiopathic (of unknown cause) gastric acid hypersecretion (IGH). Patients (n=21) being treated with a PPI for ZES (n=19) or IGH (n=2) were switched to NEXIUM 40 mg twice daily (n=19) or NEXIUM 80 mg twice daily (n=2). At baseline and day 10, patients received a gastric analysis (i.e., basal AO test) to measure the amount of acid secreted by the stomach. Patients with controlled AO at day 10 remained on their current dose and were re-tested at three, six and 12 months. In those with uncontrolled acid, doses were titrated up to as high as 240 mg/day until AO was controlled. (Investigators could increase the dose of NEXIUM at their discretion throughout the trial.) Patients underwent an endoscopy at baseline, at six months and at 12 months to check for the presence of gastric or duodenal ulcers and/or erosive esophagitis. NEXIUM was generally well tolerated at all doses.


Related medicine news :

1. Patients on NSAIDS have reduced gastric ulcers risk by Nexium?
2. Emphysema surgery - unbeneficial
3. Blood transfusions beneficial after heart attacks
4. Surgery beneficial in Menieres disease
5. Drinking wine beneficial in dementia
6. Lowering blood pressure beneficial for PAD patients
7. Green tea beneficial in preventing osteoarthritis
8. Losing weight is beneficial for osteoarthritis for the knee
9. Exercise to childrens with congenital disease beneficial
10. Combination of Schizophrenia drugs not beneficial
11. Shared decision making in health care not beneficial to patient
Post Your Comments:

(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... ... 2017 , ... As health professionals work to improve their approach to healthcare, ... doing more than filling out a survey; in many cases health professionals and patients ... health care and research on the importance of active engagement with patients and members ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology: